Phase I Clinical Study Evaluating the Relative Bioavailability of Different Formulations of HRS-5346 in Healthy Participants

This study is a single center, randomized, open label crossover trial planned to include 50 healthy participants to evaluate the relative bioavailability of HRS-5346 new and old formulations in healthy participants. The experimental process includes three stages: screening period, baseline period, and administration observation period.

NCT Number	NCT07752069
Lead Sponsor	Shandong Suncadia Medicine Co., Ltd.
Conditions	Lipoprotein Disorder
Enrollment	50 participants
Start Date	2026-08
Primary Completion	2026-09 (estimated)
Study Completion	2026-10 (estimated)
Updated on ClinicalTrials.gov	2026-08-07